**Binv-p**

**FDA approval**

In response to the FDA approval of talazoparib for the treatment of HER2-negative tumors and germline BRCA 1/2 mutation the panel voted on the addition of talazoparib for this indication.

Based on the data in the noted references, the panel consensus was to include talazoparib as a preferred option for include talazoparib for patients with recurrent or stage IV (M1), HER2-negative disease and germline BRCA 1/2 mutation. This is a category 1 recommendation.

See Submission for References.

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>0</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>

**Binv-p**

**External request:**

Submission from Pfizer Inc. to recommend the addition of talazoparib for the treatment of adult patients with deleterious or suspected deleterious BRCAm HER2-negative locally advanced or metastatic breast cancer.

Based on the data in the noted reference, the panel consensus was to change the NCCN Category of Evidence and Consensus from category 2A to category 1 for olaparib as a preferred option for patients with recurrent or stage IV (M1), HER2-negative disease and germline BRCA 1/2 mutation.


**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>0</td>
<td>1</td>
<td>8</td>
</tr>
</tbody>
</table>

**Binv-p**

**Internal request:**

Request to change the NCCN Category of Evidence and Consensus of olaparib as an option for patients with recurrent or stage IV (M1), HER2-negative disease and germline BRCA 1/2 mutation. Is this recommendation supported by high-level evidence?

Based on the data in the noted reference, the panel consensus was to change the NCCN Category of Evidence and Consensus from category 2A to category 1 for olaparib as a preferred option for patients with recurrent or stage IV (M1), HER2-negative disease and germline BRCA 1/2 mutation.